Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 6/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 5/20 | 0.37 |
| ▸ | KRAS | P01116 | 4/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3920287 | 0.89 | CASR (0.46) | CASRROCK2ROCK1SOS1KRAS | |
| SCHEMBL3931187 | 0.88 | CASR (0.55) | CASRATMTLR9TLR8TLR7 | |
| SCHEMBL13868508 | 0.88 | CASR (0.42) | CASRROCK2ROCK1SOS1KRAS | |
| SCHEMBL3922202 | 0.87 | CASR (0.48) | CASRROCK2ROCK1SOS1KRAS | |
| SCHEMBL3922588 | 0.85 | CASR (0.58) | CASRATMROCK2ROCK1 | |
| SCHEMBL3931175 | 0.83 | CASR (0.52) | CASRROCK2ROCK1SOS1KRAS | |
| SCHEMBL3925480 | 0.83 | F2 (0.42) | CASR | |
| SCHEMBL3932217 | 0.83 | CASR (0.47) | CASRROCK2ROCK1SOS1KRAS | |
| SCHEMBL13879973 | 0.81 | CASR (0.47) | CASRROCK2ROCK1SOS1KRAS | |
| SCHEMBL3922366 | 0.80 | CASR (0.53) | CASRROCK2ROCK1SOS1KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524873-B2 | Substituted N-phenylmethyl ethanamines; N-((6-(methyloxy)-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl)methyl)-1-(1-naphthalenyl)ethanamine; parathyroid hormone inhibitors; antisecretory agents; osteoporosis | AMGEN INC. (US) | 2009-04-28 | — | — | US | claimed |
| US-20070142381-A1 | Calcium receptor modulating agents | AMGEN INC. | 2007-06-21 | — | — | US | claimed |
| US-7524873-B2 | Substituted N-phenylmethyl ethanamines; N-((6-(methyloxy)-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl)methyl)-1-(1-naphthalenyl)ethanamine; parathyroid hormone inhibitors; antisecretory agents; osteoporosis | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070142381-A1 | Calcium receptor modulating agents | AMGEN INC. | 2007-06-21 | — | — | US | disclosed |
| US-7196102-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. | 2005-06-30 | — | — | US | disclosed |
| US-6908935-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040082625-A1 | Calcium receptor modulating agents | AMGEN INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082625-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | CASR 2/4885ATM 4317/4885TLR9 801/4885 |
| US-20070142381-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | CASR 2/4885ATM 4144/4885TLR9 895/4885 |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | PTH1R, PTMS, SOST | CASR 24/4885ATM 3320/4885TLR9 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.